Amgen to present its four Phase 3 clinical trial results Amgen today announced it’ll present detailed data from four Phase 3 studies along with other data in the ECCO 15 – ESMO 34 European Multidisciplinary Congress, September 20 – 24, 2009 in Berlin, Germany. Researchers will show data from two Stage 3 head-to-head studies evaluating denosumab versus Zometa for the treating bone metastases in sufferers with advanced breast tumor and the treatment of bone metastases in advanced cancer sufferers with solid tumors or multiple myeloma http://dmae.review/ . Related StoriesMD Anderson study reveals why chemotherapy medicines not effective for many pancreatic cancer patientsStudy displays uncommon HER2 missense mutations usually do not spread breast cancer on their ownNew RNA check of blood platelets may be used to detect location of cancerDetailed data will also be offered from two Stage 3 studies analyzing Vectibix in conjunction with chemotherapy for the first-line and second-collection treatment of metastatic colorectal cancer tumor .
A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing effective and safe medicines from laboratory, to manufacturing plant, to patient. Amgen therapeutics have transformed the practice of medication, helping millions of people all over the world in the fight cancer, kidney disease, arthritis rheumatoid and other serious ailments. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. For more information about our pioneering science and our vital medicines, visit About the Amgen Base The Amgen Foundation ( seeks to advance research education, improve patient access to quality care, and fortify the communities where Amgen staff members live and work.